Shareholders Sue Novo Nordisk Over Misleading Claims on Weight-Loss Drug CagriSema

Investors have filed a lawsuit against Novo Nordisk, alleging the company misled the market about the tolerability of its next-generation weight-loss drug CagriSema. Disappointing clinical trial results regarding side effects wiped billions off the company's market capitalisation. Shareholders claim Novo Nordisk concealed information about the drug's tolerability issues before the trial data were published.

More on this topic

🏥 Health Eli Lilly to File for Approval of Next-Gen Obesity Drug Retatrutide in 2027 CNBC · 7d ago 🏥 Health Novo Nordisk sues Eli Lilly over misleading Zepbound vs Wegovy weight-loss comparison The Independent World · 8d ago 📈 Business Novo Nordisk Sues Eli Lilly Over Misleading Weight-Loss Drug Ads The Guardian Health · 8d ago

More on this topic

🏥 Health Eli Lilly to File for Approval of Next-Gen Obesity Drug Retatrutide in 2027 CNBC · 7d ago 🏥 Health Novo Nordisk sues Eli Lilly over misleading Zepbound vs Wegovy weight-loss comparison The Independent World · 8d ago 📈 Business Novo Nordisk Sues Eli Lilly Over Misleading Weight-Loss Drug Ads The Guardian Health · 8d ago